Melius Pharma is a pharmaceutical company focusing on the development of new treatments for interstitial lung diseases.
Melius Pharma’s lead project for chronic cough in idiopathic pulmonary fibrosis is about to enter a phase 2a clinical proof of concept study. Chronic cough is a serious symptom in idiopathic pulmonary fibrosis that severely affects the quality of life in patients suffering from this disease. Median survival for patients after diagnosis is 3–5 years with current treatments.
Melius Pharma’s drug candidate is a new chemical entity benefiting from more than 20 years of safety data in man as well as efficacy data from both clinical and preclinical cough studies thus providing for a de-risk development.
